Halladay Benjamin, CFO of Esperion Therapeutics ($ESPR), sold shares on the open market six times over the past year for a total of $60,280. His latest sale occurred on December 17, 2025. These transactions rank 10,180th out of 11,678 insiders by sale value, well below the $8.6 million average, with no open market purchases recorded.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 17, 2026 | Esperion Therapeutics, Inc. | $ESPR | Halladay Benjamin | Chief Financial Officer | S | Common Stock | 6424 | $2.71 | 713,602.0000 | 239,063,437 | 0.89% | 0.00% |
| March 13, 2026 | Esperion Therapeutics, Inc. | $ESPR | Halladay Benjamin | Chief Financial Officer | A | Common Stock | 247430 | $0.00 | 720,026.0000 | 239,063,437 | 52.36% | 0.10% |
| March 13, 2026 | Esperion Therapeutics, Inc. | $ESPR | Halladay Benjamin | Chief Financial Officer | A | Stock Option (right to buy) | 221270 | $0.00 | 221,270.0000 | 239,063,437 | 9999.99% | 0.09% |
| Dec. 17, 2025 | Esperion Therapeutics, Inc. | $ESPR | Halladay Benjamin | Chief Financial Officer | S | Common Stock | 7337 | $3.67 | 467,525.0000 | 239,063,437 | 1.55% | 0.00% |
| Sept. 17, 2025 | Esperion Therapeutics, Inc. | $ESPR | Halladay Benjamin | Chief Financial Officer | S | Common Stock | 7046 | $2.81 | 474,862.0000 | 197,848,886 | 1.46% | 0.00% |
| July 17, 2025 | Esperion Therapeutics, Inc. | $ESPR | Halladay Benjamin | Chief Financial Officer | S | Common Stock | 11 | $1.12 | 474,462.0000 | 197,848,886 | 0.00% | 0.00% |
| June 17, 2025 | Esperion Therapeutics, Inc. | $ESPR | Halladay Benjamin | Chief Financial Officer | S | Common Stock | 7229 | $1.15 | 474,473.0000 | 197,848,886 | 1.50% | 0.00% |
| April 17, 2025 | Esperion Therapeutics, Inc. | $ESPR | Halladay Benjamin | Chief Financial Officer | S | Common Stock | 8 | $0.96 | 481,702.0000 | 197,848,886 | 0.00% | 0.00% |
| March 18, 2025 | Esperion Therapeutics, Inc. | $ESPR | Halladay Benjamin | Chief Financial Officer | S | Common Stock | 3535 | $1.48 | 481,710.0000 | 197,848,886 | 0.73% | 0.00% |
| March 14, 2025 | Esperion Therapeutics, Inc. | $ESPR | Halladay Benjamin | Chief Financial Officer | A | Common Stock | 238000 | $0.00 | 485,245.0000 | 197,848,886 | 96.26% | 0.12% |
| March 14, 2025 | Esperion Therapeutics, Inc. | $ESPR | Halladay Benjamin | Chief Financial Officer | A | Stock Option (right to buy) | 213000 | $0.00 | 213,000.0000 | 197,848,886 | 9999.99% | 0.11% |
| Feb. 19, 2025 | Esperion Therapeutics, Inc. | $ESPR | Halladay Benjamin | Chief Financial Officer | S | Common Stock | 11 | $1.86 | 240,671.0000 | 0 | 0.00% | 0.00% |
| Jan. 17, 2025 | Esperion Therapeutics, Inc. | $ESPR | Halladay Benjamin | Chief Financial Officer | S | Common Stock | 9 | $2.27 | 240,682.0000 | 0 | 0.00% | 0.00% |
| Dec. 17, 2024 | Esperion Therapeutics, Inc. | $ESPR | Halladay Benjamin | Chief Financial Officer | S | Common Stock | 3245 | $2.42 | 240,691.0000 | 0 | 1.33% | 0.00% |
| March 14, 2024 | Esperion Therapeutics, Inc. | $ESPR | Halladay Benjamin | Chief Financial Officer | A | Common Stock | 170000 | $0.00 | 243,936.0000 | 0 | 229.93% | 0.00% |
| March 14, 2024 | Esperion Therapeutics, Inc. | $ESPR | Halladay Benjamin | Chief Financial Officer | A | Stock Option (right to buy) | 200000 | $0.00 | 200,000.0000 | 0 | 9999.99% | 0.00% |